Friday 6 November 2026
Export DVA’s income statement to Excel — free account
DaVita Inc.
DVA Healthcare Medical Care Facilities
DaVita Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 billion, up 6.46% from fiscal 2024.
- Revenue
- +4.62%
- EPS
- +67.0%
- Free cash flow
- −45.8%
- Total debt
- +5.07%
Quarter to September 2026, against a year earlier
189.65
5.17
−2.65%
Follow DVA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
11.23 | 13.97 | 17.83 | 12.60 |
P/S ratio |
0.62 | 0.75 | 1.03 | 0.79 | |
P/FCF ratio |
5.56 | 6.12 | 8.01 | 7.52 | |
P/Operating CF |
15.60 | 32.28 | 29.41 | 21.52 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.33 | 1.47 | 1.75 | 1.51 | |
EV/EBITDA |
6.57 | 7.25 | 8.62 | 7.57 | |
EV/Operating CF |
9.61 | 10.02 | 11.15 | 11.41 | |
EV/FCF |
11.94 | 12.00 | 13.59 | 14.37 | |
Quick Ratio |
1.19 | 1.31 | 1.36 | 1.31 | |
Current Ratio |
1.29 | 1.42 | 1.47 | 1.41 | |
Net Debt/EBITDA |
12.96 | 15.10 | 13.45 | 15.31 | |
Debt/Assets |
59.91% | 61.22% | 61.08% | 60.75% | |
Debt/Equity |
(28.02) | (22.49) | (22.44) | (30.19) | |
Asset Turnover |
0.78 | 0.80 | 0.80 | 0.80 | |
Operating CF/Net income |
2.31 | 1.62 | 1.85 | 2.33 | |
Capex/Depreciation |
(0.77) | (0.55) | (1.01) | (0.89) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
13.05% | 12.35% | 11.91% | 11.42% | |
Intangible Assets out of Total Assets |
0.44 | 0.45 | 0.44 | 0.44 | |
Share Based Compensation of Revenue |
1.06% | 0.82% | 0.73% | 0.82% | |
Graham Net Nets |
(1.64) | (1.34) | (0.97) | (1.26) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
8.91% | 7.16% | 5.61% | 7.94% | |
Free Cash Flow Yield |
18.00% | 16.35% | 12.48% | 13.30% | |
Revenue per Share |
48.77 | 50.68 | 54.86 | 56.05 | |
Operating CF per Share |
7.28 | 4.76 | 7.57 | 8.13 | |
Capex per Share |
(1.93) | (1.46) | (2.61) | (2.31) | |
Free Cash Flow per Share |
5.35 | 3.30 | 4.95 | 5.82 | |
Cash per Share |
10.54 | 11.11 | 11.91 | 10.18 | |
Shareholders Equity per Share |
(5.03) | (7.07) | (7.44) | (5.62) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(5.03) | (7.07) | (7.44) | (5.62) | |
Free Cash Flow |
397.13 | 222.53 | 320.92 | 371.25 | |
Working Capital |
916.37 | 1,195.22 | 1,334.21 | 1,188.06 | |
Capital Expenditures |
(143.59) | (98.30) | (169.15) | (147.58) | |
Net Current Asset Value |
(13,795.84) | (13,913.02) | (14,001.83) | (14,100.16) | |
EV/EBIT |
8.87 | 9.74 | 11.50 | 10.06 | |
Capex to Sales |
0.04 | 0.03 | 0.05 | 0.04 | |
Price to Operating Income |
4.13 | 4.96 | 6.77 | 5.26 | |
| Other line items | |||||
Average Receivables |
2,758.36 | 2,885.38 | 3,060.22 | 3,054.05 | |
Average Payables |
621.67 | 643.70 | 655.14 | 658.90 | |
Average Inventory |
147.59 | 146.07 | 148.92 | 150.28 | |
Average Assets |
17,382.69 | 17,309.20 | 17,601.23 | 17,686.20 | |
Average Common Equity |
11.07 | (241.45) | (294.97) | (331.35) |
Columns are period end dates · fundamentals updated 5 Nov 2026